BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1557 related articles for article (PubMed ID: 22402316)

  • 21. [The mechanisms of prostate cancer progression through androgen receptor].
    Goto Y; Sakamoto S; Ichikawa T
    Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen action and metabolism in prostate cancer.
    Green SM; Mostaghel EA; Nelson PS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
    Agoulnik IU; Weigel NL
    J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor signaling in androgen-refractory prostate cancer.
    Grossmann ME; Huang H; Tindall DJ
    J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
    Chatterjee B
    Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
    Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
    Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathogenesis and progression of prostate cancer.
    Schrecengost R; Knudsen KE
    Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of androgens and the androgen receptor in prostate cancer.
    Debes JD; Tindall DJ
    Cancer Lett; 2002 Dec; 187(1-2):1-7. PubMed ID: 12359344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
    Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
    Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
    Lyons LS; Burnstein KL
    Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular regulation of androgen action in prostate cancer.
    Dehm SM; Tindall DJ
    J Cell Biochem; 2006 Oct; 99(2):333-44. PubMed ID: 16518832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.